Meeting
2013 ASCO Annual Meeting
PERSEPHONE: Duration of trastuzumab with chemotherapy in women with HER2-positive early breast cancer—Six versus twelve months.
Authors
Helena Margaret Earl
University of Cambridge, Department of Oncology, Cambridge, United Kingdom
Helena Margaret Earl , David A. Cameron , David Miles , Andrew M. Wardley , Emma Ogburn , A-L Vallier , Shrushma Loi , Helen B Higgins , Louise Hiller , Janet A. Dunn
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Clinical Trial Registration Number
52968807
Citation
J Clin Oncol 31, 2013 (suppl; abstr TPS667)
DOI
10.1200/jco.2013.31.15_suppl.tps667
Abstract #
TPS667
Poster Bd #
17C
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
PERSEPHONE: Duration of trastuzumab with chemotherapy in patients with HER2-positive early breast cancer—Six versus twelve months.
First Author: Helena Margaret Earl
Poster
2012 ASCO Annual Meeting
The PERSEPHONE trial: Duration of trastuzumab with chemotherapy in women with HER2-positive early breast cancer.
First Author: Helena Margaret Earl
Poster
2021 ASCO Annual Meeting
Phase II prospective open label study of neoadjuvant pertuzumab, trastuzumab, and nab-paclitaxel in patients with HER-2 positive advanced breast cancer.
First Author: Sayeh Moazami Lavasani
Poster
2019 ASCO Annual Meeting
Is neratinib following trastuzumab in early-stage HER2-positive breast cancer cost-effective?
First Author: Naomi RM Schwartz